

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | | |
|-------------------------------------|--|
| n/a | Confirmed |
| ☐ | ☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☐ | ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☐ | ☒ The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| ☒ | ☐ A description of all covariates tested |
| ☒ | ☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☐ | ☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted
<i>Give P values as exact values whenever suitable.</i> |
| ☒ | ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☒ | ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☒ | ☐ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	CryoEM data was collected at Sauer Structural Biology Laboratory, University of Texas at Austin and at Structural Biology Core, UT Health San Antonio, using EPU software v2.13, ThermoScientific. Bio-Rad imager was used to collect western blotting data
Data analysis	CryoEM data was processed by using the cryoSPARC 3.1. Subsequent refinement, model building and visualization was performed by using the Phenix1.20.1-4487, Coot0.9.8.7, PyMOL v2.0 and ChimeraX1.5. Graphpad Prism (versions 9) was used for statistical analyses Image Lab 5.2.1 (Bio-Rad) was used to analyze Western Blotting data and colony formation quantification

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Atomic coordinates and their corresponding maps were deposited in RCSB under the accession code PDB: 9DRJ and EMD-47127 for SUMO E1-UBC9-SUMO1(a), PDB: 9DQB and EMD-47110 for SUMO E1-UBC9-SUMO1(t)/SUMO1(a). The structural data used from RCSB for analysis are listed here- PDB: 4NNJ, PDB:3CMM, PDB:2NVU, PDB:6NYA, PDB:8SE9, PDB:8SEB, PDB:1Y8R, PDB:1Y8Q, PDB:3KYC, PDB:6CWZ, PDB:5JNE, PDB: 7K5J, PDB:3ONG. The source data and uncropped gels/blots are provided as a Source Data file.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	NA
Reporting on race, ethnicity, or other socially relevant groupings	NA
Population characteristics	NA
Recruitment	NA
Ethics oversight	NA

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No sample size calculation was performed. Sample sizes were indicated in the corresponding figure legends. For each biochemical assay reported in Figures 2, and 3 were conducted in triplicate since this sample size has been broadly accepted by the scientific community for such experiments. Data are represented as mean $\pm$ SD of three independent experiments. For colony formation assays, at least 3 biological repeats were performed to ensure reproducibility. Data are represented as mean $\pm$ SEM of three independent experiments. For western blotting, the experimental findings were confirmed using two independent experiments.
Data exclusions	No data were excluded from any of the analysis except junk 2D and 3D classes in CryoSPARC during CryoEM data processing.
Replication	All the biochemical assays were repeated as three distinct technical replicates. All of the data were consistent and were included. For cell-based assays were performed in triplicate and repeated at least two times.
Randomization	In these investigations, experimental grouping was not used, hence randomization was not required. All in vitro assays were done in triplicate with no randomization.
Blinding	Not relevant for this study since no bias could be introduced by the subject in the experiments performed.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

n/a	Involved in the study
☐	☒ Antibodies
☐	☒ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used

List of the antibodies used for western blot analysis
 Uba2, Cell signaling technologies, cat#8688S, 1:1000 (dilution)
 Flag, Sigma, cat#F-3165, 1:1000 (dilution)
 Beta actin, Sigma, cat#A-2066, 1:20,000 (dilution)
 Vinculin, Sigma, cat#V9264, 1:1000 (dilution)
 Ubc9, Cell signaling technologies, cat#4918S, 1:1000 (dilution)
 SUMO-1, Santa cruz, cat#sc-5308, 1:1000 (dilution)
 SUMO-2/3/4, Santa cruz, cat#sc-393144, 1:1000 (dilution)
 c-Myc, Santa cruz, cat#sc-40, 1:500, 1:1000 (dilution)
 Anti-mouse IgG HRP, Cell Signalling, cat#7076, 1:1000 (dilution)
 Rabbit IgG HRP linked F(ab')₂, SIGMA, cat#NA9340V, 1:1000 (dilution)

Validation

All other antibodies used in this study were validated by manufacturers for that specific application (Western blotting). Relevant validating results can be found in the website of each manufacturer.

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

HCT116 VIM RFP (CCL-247EMT) cell lines were purchased from ATCC; HEK293T cells were purchased from ATCC.

Authentication

Authentication was performed by STR profiling in ATCC.

Mycoplasma contamination

All cell lines tested and negative for mycoplasma contamination.

Commonly misidentified lines
(See [ICLAC](#) register)

None